UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma (Nasdaq: URGN) announced the granting of inducement restricted stock units (RSUs) to 35 new employees who will support the commercialization of Jelmyto® and pipeline development. The grants allow for the issuance of up to 112,800 ordinary shares, which will vest equally over three years, with one-third vesting annually on the anniversary of the vesting date. The RSUs are subject to continued employment and were granted under UroGen's 2019 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) ha annunciato l'assegnazione di unità di azioni a riserva (RSU) per indennità a 35 nuovi dipendenti, i quali supporteranno la commercializzazione di Jelmyto® e lo sviluppo del pipeline. Le assegnazioni consentono l'emissione di fino a 112.800 azioni ordinarie, che matureranno equamente nel corso di tre anni, con un terzo delle azioni che matura annualmente nell'anniversario della data di maturazione. Le RSU sono soggette a impiego continuativo e sono state concesse secondo il Piano di Indennità del 2019 di UroGen, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) anunció la concesión de unidades de acciones restringidas (RSU) por inducción a 35 nuevos empleados que apoyarán la comercialización de Jelmyto® y el desarrollo de la cartera de productos. Las concesiones permiten la emisión de hasta 112,800 acciones ordinarias, que se otorgarán en partes iguales durante tres años, con un tercio de las acciones que se asignarán anualmente en el aniversario de la fecha de adquisición. Las RSU están sujetas a empleo continuo y se otorgaron bajo el Plan de Inducción de UroGen de 2019, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
UroGen Pharma (Nasdaq: URGN)은 35명의 신규 직원에게 Jelmyto®의 상용화 및 파이프라인 개발을 지원하기 위한 유도 제한 주식 단위 (RSU)를 부여한다고 발표했습니다. 이 부여는 최대 112,800주의 보통주 발행을 허용하며, 3년에 걸쳐 균등하게 분산되고, 1/3은 취득일의 기념일에 매년 취득됩니다. RSU는 지속적인 고용에 따라 부여되며, Nasdaq 상장 규칙 5635(c)(4)에 따라 UroGen의 2019 유도 계획에 따라 부여되었습니다.
UroGen Pharma (Nasdaq: URGN) a annoncé l'attribution d'unités d'actions restreintes (RSU) d'incitation à 35 nouveaux employés qui soutiendront la commercialisation de Jelmyto® et le développement de la pipeline. Les attributions permettent l'émission de jusqu'à 112 800 actions ordinaires, qui seront acquises de manière égale sur trois ans, avec un tiers acquis chaque année à l'anniversaire de la date d'acquisition. Les RSU sont soumises à un emploi continu et ont été accordées dans le cadre du Plan d'Incitation 2019 de UroGen, conformément à la règle de cotation Nasdaq 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) hat die Gewährung von Anreiz beschränkten Aktieneinheiten (RSUs) an 35 neue Mitarbeiter bekannt gegeben, die die Vermarktung von Jelmyto® und die Entwicklung der Pipeline unterstützen werden. Die Gewährungen erlauben die Ausgabe von bis zu 112.800 Stammaktien, die gleichmäßig über drei Jahre verteilt werden, wobei ein Drittel jährlich am Jahrestag des Vesting-Datums fällig wird. Die RSUs unterliegen einer fortgesetzten Anstellung und wurden im Rahmen des Anreizplans 2019 von UroGen gemäß der Nasdaq-Börsennotierungsregel 5635(c)(4) gewährt.
- Expansion of workforce with 35 new employees to support commercialization and development efforts
- Implementation of employee retention strategy through RSU grants
- Potential shareholder dilution from issuance of 112,800 new shares
Up to 112,800 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.
The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in
Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241206579709/en/
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
How many new employees received RSU grants from UroGen Pharma (URGN)?
How many shares can be issued under UroGen Pharma's (URGN) new RSU grants?
What is the vesting schedule for UroGen Pharma's (URGN) new RSU grants?
What is the purpose of UroGen Pharma's (URGN) new employee RSU grants?
